Lyra Capital Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 3

  • Investments
  • 3

Lyra Capital General Information

Description

Provider of asset management services.. The company creates, markets, and manages investable hedge fund index products, and specifically manages the Dow Jones Institutional Benchmark Series. It delivers the returns of specific hedge fund strategies without the allocation, leverage, and operational risks associated with many hedge fund structures. It conducts manager due diligence and negotiates transparency and other key terms with managers.

Contact Information

Website
www.lyracapital.com
Formerly Known As
Zurich Institutional Benchmarks Management
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 1301 Avenue of the Americas
  • 38th Floor
  • New York, NY 10019
  • United States
Primary Industry
Asset Management
Corporate Office
  • 1301 Avenue of the Americas
  • 38th Floor
  • New York, NY 10019
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lyra Capital Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lyra Capital‘s full profile, request access.

Request a free trial

Lyra Capital Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Lyra Capital‘s full profile, request access.

Request a free trial

Lyra Capital Investments (3)

Lyra Capital’s most recent deal was a Early Stage VC with Kailera Therapeutics for . The deal was made on 01-Oct-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Kailera Therapeutics 01-Oct-2024 Early Stage VC Drug Discovery
ArriVent Biopharma 14-Feb-2022 Early Stage VC Pharmaceuticals
SBFC Finance Buyout/LBO Specialized Finance
To view Lyra Capital’s complete investments history, request access »

Lyra Capital Exits (2)

Lyra Capital’s most recent exit was on 14-Feb-2022 from ArriVent Biopharma. The exit was categorized as with 7 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
ArriVent Biopharma 14-Feb-2022 Completed
  • 7 buyers
SBFC Finance Buyout/LBO Completed
  • 4 buyers
To view Lyra Capital’s complete exits history, request access »

Lyra Capital FAQs

  • When was Lyra Capital founded?

    Lyra Capital was founded in 1999.

  • Where is Lyra Capital headquartered?

    Lyra Capital is headquartered in New York, NY.

  • What industry is Lyra Capital in?

    Lyra Capital’s primary industry is Asset Management.

  • Is Lyra Capital a private or public company?

    Lyra Capital is a Private company.

  • What is Lyra Capital’s current revenue?

    The current revenue for Lyra Capital is .

  • Who are Lyra Capital’s investors?

    Amundi Investment Solutions and Capital Z Partners have invested in Lyra Capital.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »